The therapeutic mechanism of MSCs in the systemic form of scleroderma includes the induction of apoptosis in activated T cells via activation of the Fas/Fas ligand pathway, leading to ameliorating autoimmune phenotypes and reducing hypodermal thickness [330, 331]. The gene discussed is FAS; the disease is scleroderma.